DiaMedica Therapeutics Inc (DMAC)
Healthcare
Biotechnology
6.30 $
-2.6%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns DiaMedica Therapeutics Inc (DMAC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 53.4% of the shares are freely tradable; institutional investors hold 37.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
37.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
27.7%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
53.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
13.4%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
54Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Cooperman Leon G | 3.75 | 2,020,000 | +0.0 | 03/31/2026 |
| BlackRock Inc | 3.44 | 1,856,187 | -2.4 | 03/31/2026 |
| Millennium Management LLC | 1.74 | 935,592 | +21.7 | 03/31/2026 |
| PARAGON Assoc & PARAGON Assoc II JV | 1.62 | 875,000 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 1.45 | 780,516 | +2.1 | 03/31/2026 |
| Vanguard Group Inc | 1.34 | 723,120 | +8.8 | 12/31/2025 |
| State Street Corp | 1.20 | 644,211 | +2.6 | 03/31/2026 |
| First Manhattan Co. LLC | 0.84 | 455,000 | +12.3 | 03/31/2026 |
| Bleichroeder LP | 0.71 | 382,317 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.50 | 805,956 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.